Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02514213 · ClinicalTrials.gov registry record · Phase 1
Trial to Evaluate Safety and Immunogenicity of INO-5150 Alone or With INO-9012 in Men With Prostate Cancer
A Phase 1 study, sponsored by Inovio Pharmaceuticals.
- Completed
- Registry status
- Phase 1
- Development phase
- 62
- Enrollment target
NCT02514213: Completed Phase 1 study, sponsored by Inovio Pharmaceuticals.
NCT02514213 is a Phase 1 study that has completed, run by Inovio Pharmaceuticals. The registered enrollment target is 62 participants, roughly in line with the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02514213, a Phase 1 study, has completed, sponsored by Inovio Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 62 participants
- Enrollment target
Study Summary
This is a phase I, open-label trial to evaluate the safety and immunogenicity of INO 5150 alone or in combination with INO-9012 when delivered intramuscularly (IM) followed by electroporation (EP) in men with biochemically relapsed prostate cancer.
Primary Outcome
1. Incidence of adverse events (all, severe, \[NCI CTCAE v4.03\] and serious) classified by system organ class (SOC), preferred term, severity, and relationship to study medication and schedule 2. Injection site reactions 3. Changes in safety laboratory parameters .
Interventions
- BIOLOGICAL 2mg INO-5150 and electroporation device CELLECTRA®-5P
- BIOLOGICAL 8.5mg INO-5150 and electroporation device CELLECTRA®-5P
- BIOLOGICAL 2mg INO-5150 plus 1mg INO-9012 and electroporation device CELLECTRA®-5P
- BIOLOGICAL 8.5mg INO-5150 plus 1mg INO-9012 and electroporation device CELLECTRA®-5P
- DEVICE Electroporation using CELLECTRA®-5P
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 62 participants |
| Start Date | 2015-07 |
| Est. Completion | 2017-12-12 |
| Phase | Phase 1 |
What the finished NCT02514213 record still lists
NCT02514213 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 62 participants, a relatively small participant target, roughly in line with the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target.
The record links to 0 conditions, and to 5 interventions - of which 2mg INO-5150 and electroporation device CELLECTRA®-5P is the first listed.
NCT02514213 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02514213 about?
NCT02514213 is a clinical study titled "Trial to Evaluate Safety and Immunogenicity of INO-5150 Alone or With INO-9012 in Men With Prostate Cancer". This is a phase I, open-label trial to evaluate the safety and immunogenicity of INO 5150 alone or in combination with INO-9012 when delivered intramuscularly (IM) followed by electroporation (EP) in men with biochemically relapsed prostate cancer.
What is the current status of trial NCT02514213?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 62 participants. The study started on 2015-07. Estimated completion is 2017-12-12.
What interventions are being tested in trial NCT02514213?
The interventions under investigation include: 2mg INO-5150 and electroporation device CELLECTRA®-5P (BIOLOGICAL), 8.5mg INO-5150 and electroporation device CELLECTRA®-5P (BIOLOGICAL), 2mg INO-5150 plus 1mg INO-9012 and electroporation device CELLECTRA®-5P (BIOLOGICAL), 8.5mg INO-5150 plus 1mg INO-9012 and electroporation device CELLECTRA®-5P (BIOLOGICAL), Electroporation using CELLECTRA®-5P (DEVICE).
Who is sponsoring clinical trial NCT02514213?
This trial is sponsored by Inovio Pharmaceuticals, which has 28 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02514213's enrollment target sits among peer trials
62 824th of 2000 higher than 1,173 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03231150 · 62 participants · NA
Plantar Fasciitis Randomized Clinical Control Trial
- NCT03458676 · 62 participants · NA
Radiologic Pathologic Correlation of Advanced MR Imaging to Guide the Biopsy of Cerebral Malignancies
- NCT03596086 · 62 participants · Phase 1
HSV-tk + Valacyclovir + SBRT + Chemotherapy for Recurrent GBM
- NCT03603405 · 62 participants · Phase 1
HSV-tk and XRT and Chemotherapy for Newly Diagnosed GBM
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia